Cisplatin + Gemcitabine + Placebo + bevacizumab [Avastin] + bevacizumab [Avastin]
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
Feb 1, 2005 → Feb 1, 2011
NCT ID
NCT00806923About Cisplatin + Gemcitabine + Placebo + bevacizumab [Avastin] + bevacizumab [Avastin]
Cisplatin + Gemcitabine + Placebo + bevacizumab [Avastin] + bevacizumab [Avastin] is a phase 3 stage product being developed by Roche for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00806923. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (3) Terminated (2) Active (15)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00806923 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer